Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
ConditionAdvanced Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorWenjin Yin
About this trial
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Eligibility criteria
Qualifiers
Age≥18 years old
Pathologically confirmed advanced or locally advanced breast cancer not amenable to curative surgery
Pathologically confirmed HER2+ at least once for either primary or metastatic lesion
Previously treated with any number of lines for advanced disease and eligible for a pyrotinib-containing regimen at the discretion of physician
Disqualifiers
During pregnancy and lactation
Difficulties with pyrotinib administration or absorption
Trial design
Treatments tested in this trial
- Pyrotinib
Treatment groups
186 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wenjin Yin
Lead sponsor
RenJi Hospital
Sponsor institution
Source ClinicalTrials.gov